A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3183 participants.
Also called NCT02692716
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,183 participants
- Sponsor
- Registry
-
NCT02692716 -
2015-003563-10
-
- Other papers using this trial's data
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Algeria, Argentina, Brazil, Canada, Denmark, Germany, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Romania, South Africa, Spain, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02692716. Randomized; double masking; primary purpose treatment. Start 2017-01-17 (actual); primary completion 2018-09-25 (actual). Results posted on 2020-02-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
- Acronym
- PIONEER 6
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02692716- Content hash
c00b8694ef310a5c6f37b964bc416a7105bc892144f29e1a0d7ad4db333a6ae6